Analyst Ratings For Caladrius Biosciences (NASDAQ:CLBS)
Today, HC Wainwright reiterated its Buy rating on Caladrius Biosciences (NASDAQ:CLBS) with a price target of $12.00.
Some recent analyst ratings include
- 3/14/2018-HC Wainwright Reiterated Rating of Buy.
- 11/9/2016-Chardan Capital Reiterated Rating of Buy.
- 5/14/2016-Maxim Group Reiterated Rating of Hold.
- 4/30/2016-Rodman & Renshaw Upgrade from a “Buy” rating to a “” rating.
Recent Insider Trading Activity For Caladrius Biosciences (NASDAQ:CLBS)
Caladrius Biosciences (NASDAQ:CLBS) has insider ownership of 13.10% and institutional ownership of 5.75%.
- On 2/7/2017 Eric Wei, Director, sold 6,575 with an average share price of $4.77 per share and the total transaction amounting to $31,362.75.
- On 2/6/2017 Eric Wei, Director, sold 8,425 with an average share price of $4.61 per share and the total transaction amounting to $38,839.25.
- On 7/1/2016 Eric Wei, Director, sold 87,500 with an average share price of $0.60 per share and the total transaction amounting to $52,500.00.
- On 6/24/2016 Eric Wei, Director, sold 22,698 with an average share price of $0.55 per share and the total transaction amounting to $12,483.90.
- On 8/17/2015 David J Mazzo, CEO, bought 20,000 with an average share price of $1.40 per share and the total transaction amounting to $28,000.00.
- On 8/11/2015 Robert S Vaters, CFO, bought 81,000 with an average share price of $1.24 per share and the total transaction amounting to $100,440.00.
- On 12/9/2014 Steven S Myers, Director, bought 20,000 with an average share price of $3.56 per share and the total transaction amounting to $71,200.00.
Recent Trading Activity for Caladrius Biosciences (NASDAQ:CLBS)
Shares of Caladrius Biosciences closed the previous trading session at with 5.730000019073486 shares trading hands.